Back to Supplement Finder

Prolap 3 Tablet

Sold by Pharmigrow

PKR 1,250.00

View at Pharmigrow
Store
pharmigrow.com
Brand
Pharmigrow
Collected
2026-11-19

From the retailer

Homeopathic combination targeting 1st & 2nd degree uterine prolapse, menstrual cramps, pelvic pain, habitual abortion support and related pelvic complaints. KEY INGREDIENTS (Per Tablet): Aletris Far Q (EHPI) 19 mg; Ashoka Q (EHPI) 20 mg; Alfalfa Q (EHPI) 18 mg; Avena Sativa Q (EHPI) 17 mg; Helonias Q (EHPI) 19 mg; Scrophularia Q (EHPI) 18 mg; Kreasotum 30 (EHP) 15 mg; Ipecac 6x (EHP) 12 mg; Acid phos 6x (EHPI) 12 mg; Kali phos Ex (EHPI) 15 mg; Mag phos 6x (EHPI) 15 mg; Nat phos Ex (EHPI) 20 mg. DOSAGE: Mild–moderate: 1 tablet BID for 6–8 weeks. Severe: 1 tablet TID for 8–12 weeks or as directed by a healthcare professional. INSTRUCTIONS: Keep out of reach of children. Protect from light and moisture. Store in a cool, dry place. How It Works Synergistic homeopathic botanicals aim to support pelvic tissue tone, reduce spasmodic pain and assist symptomatic relief in pelvic floor conditions. Key Benefits ✔ Supports symptomatic management of uterine prolapse ✔ Relieves menstrual cramps and pelvic discomfort ✔ Adjunct support for pelvic and reproductive concerns Active Ingredients (Per Tablet) Aletris Far Q (EHPI): 19 mg Ashoka Q (EHPI): 20 mg Alfalfa Q (EHPI): 18 mg Avena Sativa Q (EHPI): 17 mg Helonias Q (EHPI): 19 mg Scrophularia Q (EHPI): 18 mg Kreasotum 30 (EHP): 15 mg Ipecac 6x (EHP): 12 mg Acid phos 6x (EHPI): 12 mg Kali phos Ex (EHPI): 15 mg Mag phos 6x (EHPI): 15 mg Nat phos Ex (EHPI): 20 mg Dosage Follow the stated dosing regimen or your clinician’s instructions for pelvic conditions. Usage Instructions Store in a cool, dry place Protect from light & moisture Keep out of reach of children Safety Use as adjunctive care; consult a gynecologist for diagnosed prolapse or surgical indications. Frequently Asked Questions ❓ What is Prolap 3? A homeopathic tablet for symptomatic pelvic and prolapse-related complaints. ⚕️ How long to take it? Dosing varies by severity—commonly 6–12 weeks; follow healthcare guidance. 👤 Who should use it? Patients with mild–moderate pelvic floor symptoms as part of a clinician-led plan.